Based on the Vanda Pharmaceuticals Inc stock forecast from 1 analysts, the average analyst target price for Vanda Pharmaceuticals Inc is USD 12.33 over the next 12 months. Vanda Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Vanda Pharmaceuticals Inc is Neutral, which is based on 7 positive signals and 6 negative signals. At the last closing, Vanda Pharmaceuticals Inc’s stock price was USD 5.40. Vanda Pharmaceuticals Inc’s stock price has changed by +12.73% over the past week, +21.62% over the past month and +58.36% over the last year.
No recent analyst target price found for Vanda Pharmaceuticals Inc
No recent average analyst rating found for Vanda Pharmaceuticals Inc
Company Overview Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. Read Less
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets...Read More
Frequently Asked Questions About Vanda Pharmaceuticals Inc (VNDA) Stock
Based on ratings from 1 analysts Vanda Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on VNDA's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for VNDA is USD 12.33 over the next 12 months. The maximum analyst target price is USD 13 while the minimum anlayst target price is USD 11.
VNDA stock's Price/Earning ratio is 126.00.
Our analysis grades VNDA stock's Price / Earning ratio at F. This means that VNDA stock's Price/Earning ratio is above 91% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this VNDA may be a overvalued for its sector.
The last closing price of VNDA's stock was USD 5.40.
The most recent market capitalization for VNDA is USD 0.27B.
Based on targets from 1 analysts, the average taret price for VNDA is projected at USD 12.33 over the next 12 months.
This means that VNDA's stock price may go up by +128.40% over the next 12 months.
We can't find any ETFs which contains Vanda Pharmaceuticals Inc's stock.
As per our most recent records Vanda Pharmaceuticals Inc has 203 Employees.
Vanda Pharmaceuticals Inc's registered address is 2200 Pennsylvania Avenue NW, Washington, DC, United States, 20037.
You can get more information about it from Vanda Pharmaceuticals Inc's website at https://www.vandapharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Vanda Pharmaceuticals Inc (VNDA) Stock
Based on ratings from 1 analysts Vanda Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on VNDA's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for VNDA is USD 12.33 over the next 12 months. The maximum analyst target price is USD 13 while the minimum anlayst target price is USD 11.
VNDA stock's Price/Earning ratio is 126.00.
Our analysis grades VNDA stock's Price / Earning ratio at F. This means that VNDA stock's Price/Earning ratio is above 91% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this VNDA may be a overvalued for its sector.
The last closing price of VNDA's stock was USD 5.40.
The most recent market capitalization for VNDA is USD 0.27B.
Based on targets from 1 analysts, the average taret price for VNDA is projected at USD 12.33 over the next 12 months.
This means that VNDA's stock price may go up by +128.40% over the next 12 months.
We can't find any ETFs which contains Vanda Pharmaceuticals Inc's stock.
As per our most recent records Vanda Pharmaceuticals Inc has 203 Employees.
Vanda Pharmaceuticals Inc's registered address is 2200 Pennsylvania Avenue NW, Washington, DC, United States, 20037.
You can get more information about it from Vanda Pharmaceuticals Inc's website at https://www.vandapharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for VNDA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
